Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IO102-IO103 Plus Pembrolizumab vs Pembrolizumab in Advanced Melanoma
2024-511996-13-00Phase 3Completed
- Sponsor
- IO Biotech
- Start
- Apr 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial in melanoma comparing IO102-IO103 + pembrolizumab with Pembrolizumab monotherapy (2 arms). Primary endpoint: Progression-free survival (PFS). Started Apr 2024; status: completed.
02
Drugs
PD-L1/IDO peptide vaccinepembrolizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2024-511996-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511996-13-00.